Alzinova AB

Equities

ALZ

SE0007413455

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 16:18:08 17/07/2024 BST			5-day change	1st Jan Change
2.08 ^SEK	+2.97%		+30.00%	-31.47%

07-09	Alzinova AB Announces All Patients in the High-Dose Cohort of the Phase 1B Study	CI
06-18	Alzinova AB Announces All Patients Have Been Recruited in the High-Dose Part of Alzinova's Phase 1B Study	CI

Alzinov AB Announces Drug Substance for the ALZ-101 Vaccine is Now Produced

January 08, 2021 at 07:01 am

Alzinov AB has as secured materials for the clinical Phase 1b study through the manufacturing of the drugubstance for t the oligomer -specific vaccine ALZ-101. The high-purity material meets the quality requirements of the clinical trial. The clinical trial with ALZ-101 on Alzheimer's disease patients is expected to start during the second quarter of 2021.

Latest news about Alzinova AB

Alzinova AB Announces All Patients in the High-Dose Cohort of the Phase 1B Study	07-09	CI
Alzinova AB Announces All Patients Have Been Recruited in the High-Dose Part of Alzinova's Phase 1B Study	06-18	CI
Alzinova AB Announces New External Safety Review for Phase 1b Study	06-10	CI
Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-28	CI
Sweden’s IRLAB Therapeutics Names New CEO	05-27	MT
Alzinova AB Announces the First Patient Dosed with A Higher Dose in the Company's Phase 1B Study (Part A2) with the Vaccine Candidate ALZ-101	05-21	CI
Sweden’s Alzinova Says CEO to Step Down by July-end	04-25	MT
Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024	04-25	CI
Alzinova AB Completes In-Depth Analysis of Data from Part A of Alzinova's Phase 1B Study with the Vaccine Candidate ALZ-101	04-11	CI
Alzinova AB Announces All Patients in the Extension Part of the Phase 1B Study Have Received Their Last Dose of ALZ-101	04-04	CI
Sweden's Alzinova Names Interim CFO	03-08	MT
Alzinova AB Announces CFO Changes	03-08	CI
Alzinova AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-28	CI
Alzinova Secures Regulatory Approval to Test Higher Dose of Vaccine Candidate in Ongoing Trial	02-13	MT
Alzinova AB Receives Regulatory Approval to Evaluate A Higher Dose of the Vaccine Candidate Alz-101 in the Ongoing Phase 1B Study	02-13	CI
SynAct Pharma Names New Chief Medical Officer	02-01	MT
Alzinova AB Announces Primary Analysis Confirms Positive Phase 1B Results with ALZ-101 against Alzheimer's	01-30	CI
Alzinova AB Announces Retiremet of Håkan Skogström as CFO	12-01	CI
Alzinova AB Announces Positive Phase 1b Results with the Vaccine Candidate ALZ-101 Against Alzheimer's Disease	11-29	CI
Alzinova AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
EU Medicines Regulator OKs Alzinova's Clinical Development Program for Alzheimer's Drug Candidate	26/09/23	MT
Alzinova AB Receives Positive Response from the European Medicines Agency EMA	26/09/23	CI
Alzinova Enters Peptide Production Agreement with Manufacturer	25/08/23	MT
Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/08/23	CI
Alzinova Completes Pre-IND Meeting with US FDA on Alzheimer's Drug Candidate	09/08/23	MT

Chart Alzinova AB

Duration

Period

More charts

Company Profile

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâs disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Sector

Biotechnology & Medical Research

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Alzinova AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALZINOVA AB	-31.47%	8.47M
MODERNA, INC.	+21.43%	47.96B
IQVIA HOLDINGS INC.	+1.40%	42.45B
LONZA GROUP AG	+43.85%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+26.97%	31.6B
ICON PUBLIC LIMITED COMPANY	+21.16%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+52.57%	14.56B
MEDPACE HOLDINGS, INC.	+44.73%	14.14B
BIO-TECHNE CORPORATION	+3.05%	12.58B

Other Biotechnology & Medical Research